Suppr超能文献

ETS变异体1/ETS相关蛋白81诱导前列腺上皮内瘤变及调节雄激素受体

Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.

作者信息

Shin Sook, Kim Tae-Dong, Jin Fang, van Deursen Jan M, Dehm Scott M, Tindall Donald J, Grande Joseph P, Munz Jan-Marie, Vasmatzis George, Janknecht Ralf

机构信息

Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.

出版信息

Cancer Res. 2009 Oct 15;69(20):8102-10. doi: 10.1158/0008-5472.CAN-09-0941. Epub 2009 Sep 29.

Abstract

ETS variant 1 (ETV1), also known as ETS-related protein 81, is overexpressed in prostate tumors, but whether and how this transcription factor affects tumorigenesis has remained elusive. Here, we show that ETV1 is primarily overexpressed in the most aggressive human prostate tumors. Transgenic ETV1 mice developed prostatic intraepithelial neoplasia as well as hyperplasia/neoplasia in seminal vesicles. Moreover, ETV1 cooperated with the androgen receptor (AR) to bind to the prostate-specific antigen enhancer and stimulate gene transcription. Consistent with its ability to physically interact with AR, ETV1 rendered an ETV1 binding site-driven reporter androgen inducible, and, on the other hand, ETV1 super-induced transcription from an AR binding site on androgen stimulation. In conclusion, our study substantiates that ETV1 overexpression is an underlying cause in the development of prostate and possibly also seminal vesicle cancer. Its interaction with and activation of AR provides a molecular mechanism on how ETV1 exerts its deleterious function. Thus, inhibiting ETV1 or blocking its interaction with AR may represent novel strategies in prostate cancer therapy.

摘要

ETS变异体1(ETV1),也被称为ETS相关蛋白81,在前列腺肿瘤中过度表达,但这种转录因子是否以及如何影响肿瘤发生仍不清楚。在此,我们表明ETV1主要在最具侵袭性的人类前列腺肿瘤中过度表达。转基因ETV1小鼠发生了前列腺上皮内瘤变以及精囊增生/瘤变。此外,ETV1与雄激素受体(AR)协同作用,结合到前列腺特异性抗原增强子上并刺激基因转录。与其与AR进行物理相互作用的能力一致,ETV1使一个由ETV1结合位点驱动的报告基因受雄激素诱导,另一方面,ETV1在雄激素刺激下从AR结合位点超诱导转录。总之,我们的研究证实ETV1过度表达是前列腺癌以及可能还有精囊癌发生的一个潜在原因。它与AR的相互作用及激活为ETV1如何发挥其有害功能提供了一种分子机制。因此,抑制ETV1或阻断其与AR的相互作用可能代表前列腺癌治疗的新策略。

相似文献

引用本文的文献

1
Anti-tumor activity of CDYL2b in prostate cancer.CDYL2b在前列腺癌中的抗肿瘤活性。
Cancer Lett. 2025 Aug 12;632:217987. doi: 10.1016/j.canlet.2025.217987.
9
ETS factors in prostate cancer.ETS 因素与前列腺癌。
Cancer Lett. 2022 Apr 1;530:181-189. doi: 10.1016/j.canlet.2022.01.009. Epub 2022 Jan 14.

本文引用的文献

7
Recurrent gene fusions in prostate cancer.前列腺癌中的复发性基因融合
Nat Rev Cancer. 2008 Jul;8(7):497-511. doi: 10.1038/nrc2402. Epub 2008 Jun 19.
8
Identification of prognostic biomarkers for prostate cancer.前列腺癌预后生物标志物的鉴定
Clin Cancer Res. 2008 Mar 15;14(6):1734-43. doi: 10.1158/1078-0432.CCR-07-1494.
10
A causal role for ERG in neoplastic transformation of prostate epithelium.ERG在前列腺上皮肿瘤转化中的因果作用。
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2105-10. doi: 10.1073/pnas.0711711105. Epub 2008 Feb 1.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验